Targeting BRAF in thyroid cancer
Open Access
- 19 December 2006
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 96 (1) , 16-20
- https://doi.org/10.1038/sj.bjc.6603520
Abstract
Activating mutations in the gene encoding BRAF are the most commonly identified oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have demonstrated that overexpression of activated BRAF induces malignant transformation and aggressive tumour behaviour. BRAF and other RAF kinases are frequently activated by other thyroid oncogenes and are important mediators of their biological effects including dedifferentiation and proliferation. Because current therapeutic options for patients with thyroid cancers that are aggressive and/or do not respond to standard therapies are limited, BRAF and its downstream effectors represent attractive therapeutic targets. In this review, data supporting a role for BRAF activation in thyroid cancer development and establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancer will be reviewed.Keywords
This publication has 43 references indexed in Scilit:
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Pathogenetic mechanisms in thyroid follicular-cell neoplasiaNature Reviews Cancer, 2006
- The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membraneEndocrine-Related Cancer, 2006
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?European Journal Of Cancer, 2006
- Biochemical and molecular characterization of the novel BRAFV599Ins mutation detected in a classic papillary thyroid carcinomaOncogene, 2006
- Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsAnnals of Oncology, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma: An Unusually High Prevalence of ras MutationsAmerican Journal of Clinical Pathology, 2003
- Mutations of the BRAF gene in human cancerNature, 2002